• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Pacira BioSciences, Inc. - Common Stock (NQ:PCRX)

    25.96 -0.09 (-0.35%)
    Streaming Delayed Price Updated: 11:05 AM EDT, Sep 25, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 49,043
    Open 26.09
    Bid (Size) 25.93 (2)
    Ask (Size) 25.97 (3)
    Prev. Close 26.05
    Today's Range 25.82 - 26.17
    52wk Range 13.79 - 27.98
    Shares Outstanding 44,454,792
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Pacira BioSciences
    Via GlobeNewswire
    PACIRA BIOSCIENCES INC (NASDAQ:PCRX) Emerges as a Strong Value Investing Opportunity
    PACIRA BIOSCIENCES (PCRX) is a strong value stock with undervalued P/E ratios, solid profitability, and stable finances, offering potential for long-term investors. 
    Via Chartmill

    Performance

    YTD
    +41.6%
    +41.6%
    1 Month
    +2.4%
    +2.4%
    3 Month
    +8.6%
    +8.6%
    6 Month
    +6.3%
    +6.3%
    1 Year
    +82.0%
    +82.0%

    More News

    Read More
    Pacira (PCRX) Q2 Revenue Rises 1.7%
    Via The Motley Fool
    Pacira BioSciences Inc (NASDAQ:PCRX) Reports Mixed Q2 2025 Earnings with EPS Beat but Revenue Miss
    Via Chartmill
    Earnings Scheduled For August 5, 2025
    Via Benzinga
    Earnings Scheduled For May 8, 2025
    Via Benzinga
    Pacira BioSciences Reports Second Quarter 2025 Financial Results
    From Pacira BioSciences
    Via GlobeNewswire
    Insights Ahead: Pacira BioSciences's Quarterly Earnings
    Via Benzinga
    Pacira to Report Second Quarter 2025 Financial Results on Tuesday August 5, 2025
    From Pacira BioSciences
    Via GlobeNewswire
    Pacira BioSciences Announces Strategic Collaboration to Significantly Expand ZILRETTA Promotional Efforts
    From Pacira BioSciences
    Via GlobeNewswire
    PACIRA BIOSCIENCES INC (NASDAQ:PCRX) – An Undervalued Stock Worth Considering
    Via Chartmill
    Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Pacira BioSciences
    Via GlobeNewswire
    Lifshitz Law PLLC Announces Investigations of Sun Communities, Inc. (NYSE: SUI), Pacira Biosciences, Inc. (NASDAQ: PCRX), ModivCare, Inc. (NASDAQ: MODV), and Integral Ad Science Holding Corp. (NASDAQ: IAS)
    Via ACCESS Newswire
    Pacira BioSciences Debuts Inspiring New Film Highlighting One Patient’s Journey to Pain Relief and Innovation in Care at BIO 2025
    From Pacira BioSciences
    Via GlobeNewswire
    PACIRA ALERT: Bragar Eagel & Squire, P.C. is Investigating Pacira BioSciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    PACIRA BIOSCIENCES INC (NASDAQ:PCRX) – An Undervalued Stock with Strong Fundamentals
    Via Chartmill
    Lifshitz Law PLLC Announces Investigations of DMC Global Inc. (NASDAQ: BOOM), Sun Communities, Inc. (NYSE: SUI), Pacira Biosciences, Inc. (NASDAQ: PCRX), and ModivCare, Inc. (NASDAQ: MODV)
    Via ACCESS Newswire
    Pacira BioSciences Unveils Three-Year Clinical Data Following a Single Local Administration of Investigational Gene Therapy, PCRX-201, in Patients with Moderate-to-Severe Osteoarthritis of the Knee
    From Pacira BioSciences
    Via GlobeNewswire
    Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Pacira BioSciences
    Via GlobeNewswire
    Grabar Law Office Investigates Claims on Behalf of Shareholders of DoubleVerify Holdings, Inc. (NYSE: DV); NAPCO Securities Technologies, Inc. (NASDAQ: NSSC); Pacira Biosciences, Inc. (NASDAQ: PCRX); and Treace Medical Concepts, Inc. (NASDAQ: TMCI)
    From Grabar Law Office
    Via GlobeNewswire
    PACIRA BIOSCIENCES INC (NASDAQ:PCRX) – An Undervalued Stock with Solid Fundamentals
    Via Chartmill
    Pacira BioSciences Presents New Data on the Effects of Clinical Immunogenicity on Locally Administered PCRX-201 in Patients with Moderate to Severe Osteoarthritis of the Knee
    From Pacira BioSciences
    Via GlobeNewswire
    Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences
    From Pacira BioSciences
    Via GlobeNewswire
    Where Pacira BioSciences Stands With Analysts
    Via Benzinga
    Pacira BioSciences Reports First Quarter 2025 Financial Results
    From Pacira BioSciences
    Via GlobeNewswire

    Frequently Asked Questions

    Is Pacira BioSciences, Inc. - Common Stock publicly traded?
    Yes, Pacira BioSciences, Inc. - Common Stock is publicly traded.
    What exchange does Pacira BioSciences, Inc. - Common Stock trade on?
    Pacira BioSciences, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Pacira BioSciences, Inc. - Common Stock?
    The ticker symbol for Pacira BioSciences, Inc. - Common Stock is PCRX on the Nasdaq Stock Market
    What is the current price of Pacira BioSciences, Inc. - Common Stock?
    The current price of Pacira BioSciences, Inc. - Common Stock is 25.96
    When was Pacira BioSciences, Inc. - Common Stock last traded?
    The last trade of Pacira BioSciences, Inc. - Common Stock was at 09/25/25 11:05 AM ET
    What is the market capitalization of Pacira BioSciences, Inc. - Common Stock?
    The market capitalization of Pacira BioSciences, Inc. - Common Stock is 1.15B
    How many shares of Pacira BioSciences, Inc. - Common Stock are outstanding?
    Pacira BioSciences, Inc. - Common Stock has 1B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms Of Service.